CA2536140A1 - Dosing schedule for erbb2 anticancer agents - Google Patents

Dosing schedule for erbb2 anticancer agents Download PDF

Info

Publication number
CA2536140A1
CA2536140A1 CA002536140A CA2536140A CA2536140A1 CA 2536140 A1 CA2536140 A1 CA 2536140A1 CA 002536140 A CA002536140 A CA 002536140A CA 2536140 A CA2536140 A CA 2536140A CA 2536140 A1 CA2536140 A1 CA 2536140A1
Authority
CA
Canada
Prior art keywords
methyl
inhibitor
yloxy
pyridin
quinazolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002536140A
Other languages
English (en)
French (fr)
Inventor
Samit Kumar Bhattacharya
Richard Damian Connell
James Dale Moyer
Jitesh Pranlal Jani
Dennis Alan Noe
Stefanus Johannes Steyn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2536140A1 publication Critical patent/CA2536140A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002536140A 2003-08-18 2004-08-06 Dosing schedule for erbb2 anticancer agents Abandoned CA2536140A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49591903P 2003-08-18 2003-08-18
US60/495,919 2003-08-18
PCT/IB2004/002580 WO2005016347A1 (en) 2003-08-18 2004-08-06 Dosing schedule for erbb2 anticancer agents

Publications (1)

Publication Number Publication Date
CA2536140A1 true CA2536140A1 (en) 2005-02-24

Family

ID=34193358

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002536140A Abandoned CA2536140A1 (en) 2003-08-18 2004-08-06 Dosing schedule for erbb2 anticancer agents

Country Status (18)

Country Link
US (1) US20050119288A1 (cg-RX-API-DMAC7.html)
EP (1) EP1658080A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007502807A (cg-RX-API-DMAC7.html)
KR (2) KR20060037447A (cg-RX-API-DMAC7.html)
CN (1) CN1838959A (cg-RX-API-DMAC7.html)
AR (1) AR045268A1 (cg-RX-API-DMAC7.html)
AU (1) AU2004264726A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0413745A (cg-RX-API-DMAC7.html)
CA (1) CA2536140A1 (cg-RX-API-DMAC7.html)
CO (1) CO5670356A2 (cg-RX-API-DMAC7.html)
IL (1) IL173127A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06001989A (cg-RX-API-DMAC7.html)
NO (1) NO20061252L (cg-RX-API-DMAC7.html)
RU (1) RU2328287C2 (cg-RX-API-DMAC7.html)
SG (1) SG135193A1 (cg-RX-API-DMAC7.html)
TW (1) TW200522966A (cg-RX-API-DMAC7.html)
WO (1) WO2005016347A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200600517B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003064383A2 (en) 2002-02-01 2003-08-07 Ariad Gene Therapeutics, Inc. Phosphorus-containing compounds & uses thereof
US8505468B2 (en) * 2002-11-19 2013-08-13 Sharp Kabushiki Kaisha Substrate accommodating tray
RU2350605C2 (ru) * 2003-08-14 2009-03-27 Эррей Байофарма Инк. Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
DK1667992T3 (da) 2003-09-19 2007-04-30 Astrazeneca Ab Quinazolinderivater
RS52119B (sr) * 2004-05-06 2012-08-31 Warner-Lambert Company Llc 4-fenilamino-hinazolin-6-il-amidi
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
JP2008542354A (ja) * 2005-06-03 2008-11-27 ファイザー・プロダクツ・インク 癌治療におけるｅｒｂＢ２阻害剤と他の治療薬の併用
KR20080027253A (ko) * 2005-06-16 2008-03-26 미리어드 제네틱스, 인크. 약제학적 조성물 및 이의 용도
JP2009502960A (ja) * 2005-07-27 2009-01-29 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム 膵臓癌の処置のためのゲムシタビンおよびチロシンキナーゼ阻害剤を含む組み合わせ
US8945573B2 (en) * 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
JP5709354B2 (ja) * 2005-11-14 2015-04-30 アリアド・ファーマシューティカルズ・インコーポレイテッド ｍＴＯＲ阻害剤投与によるがん患者の治療
WO2007059257A2 (en) 2005-11-15 2007-05-24 Array Biopharma Inc. N4-phenyl-quinaz0line-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
JP2009532358A (ja) * 2006-03-31 2009-09-10 マサチューセッツ・インスティテュート・オブ・テクノロジー 突然変異型ｅｇｆ受容体を発現する腫瘍の治療
EP2004165A2 (en) * 2006-04-05 2008-12-24 Novartis Pharma AG Synergistic combinations of anticancer agents for treating cancer
US20080161335A1 (en) 2006-11-14 2008-07-03 Vladyka Ronald S Oral formulations
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
CA2720983A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating melanoma
NZ580869A (en) * 2007-04-10 2011-02-25 Myriad Pharmaceuticals Inc Methods for treating cancer
WO2008124824A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Dosages and methods for the treatment of cancer
JP2010523696A (ja) * 2007-04-10 2010-07-15 ミリアド ファーマシューティカルズ， インコーポレイテッド 脳腫瘍を治療する方法
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
EP2592156B1 (en) 2007-06-08 2016-04-20 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
US8252805B2 (en) * 2008-05-07 2012-08-28 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
WO2010027848A2 (en) * 2008-08-26 2010-03-11 Teva Pharmaceutical Industries Ltd. Forms of lapatinib compounds and processes for the preparation thereof
NZ594665A (en) 2009-03-20 2013-08-30 Genentech Inc Bispecific anti-her antibodies
HK1203378A1 (en) 2011-11-23 2015-10-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
SG11201606193RA (en) 2014-01-31 2016-08-30 Toppan Printing Co Ltd Biomolecule analysis kit and biomolecule analysis method
US11160871B2 (en) 2015-10-28 2021-11-02 Tarveda Therapeutics, Inc. SSTR-targeted conjugates and particles and formulations thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA932522B (en) * 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
WO1996030347A1 (en) * 1995-03-30 1996-10-03 Pfizer Inc. Quinazoline derivatives
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
OA12291A (en) * 2000-06-22 2004-03-18 Pfizer Prod Inc Substituted bicyclic derivatives for the treatmentof abnormal cell growth.
MXPA04004107A (es) * 2001-12-12 2004-07-23 Pfizer Prod Inc Moleculas pequenas para el tratamiento del crecimiento celular anormal.
PL370858A1 (en) * 2001-12-12 2005-05-30 Pfizer Products Inc. Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production
EP1567506A4 (en) * 2002-11-20 2007-06-20 Array Biopharma Inc CYANOGUANIDINES AND CYANOAMIDINES AS INHIBITORS OF ERBB2 AND EGFR
PL377686A1 (pl) * 2002-12-18 2006-02-06 Pfizer Products Inc. Pochodne 4-anilinochinazoliny do leczenia anormalnego wzrostu komórek

Also Published As

Publication number Publication date
JP2007502807A (ja) 2007-02-15
SG135193A1 (en) 2007-09-28
US20050119288A1 (en) 2005-06-02
EP1658080A1 (en) 2006-05-24
CO5670356A2 (es) 2006-08-31
KR20060037447A (ko) 2006-05-03
KR20080014144A (ko) 2008-02-13
AU2004264726A1 (en) 2005-02-24
RU2328287C2 (ru) 2008-07-10
WO2005016347A1 (en) 2005-02-24
AR045268A1 (es) 2005-10-19
BRPI0413745A (pt) 2006-10-24
TW200522966A (en) 2005-07-16
MXPA06001989A (es) 2006-05-17
RU2006102125A (ru) 2007-09-27
IL173127A0 (en) 2006-06-11
CN1838959A (zh) 2006-09-27
NO20061252L (no) 2006-05-16
ZA200600517B (en) 2007-02-28

Similar Documents

Publication Publication Date Title
US20050119288A1 (en) Dosing schedule for a novel anticancer agent
KR102871791B1 (ko) 병용 요법
US11096947B2 (en) Combination products with tyrosine kinase inhibitors and their use
CN109069504B (zh) 氨基噻唑化合物及其用途
TW201831188A (zh) 涉及二芳基巨環化合物之組合療法
TW202007396A (zh) Bcl-2抑制劑或Bcl-2/Bcl-xL抑制劑與BTK抑制劑的組合產品及其在預防和/或治療疾病中的用途
CA2544863A1 (en) Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer
TWI762784B (zh) Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
CN118369119A (zh) KRAS G12D抑制剂与泛ErbB家族抑制剂的组合疗法
JP2023075161A (ja) 癌の処置
KR20240170920A (ko) Sos1 억제제 및 egfr 억제제를 포함하는 병용 요법
KR20210038366A (ko) Flt3 저해제 및 mdm2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
CN101222850A (zh) 治疗对药物有抗性的癌症的方法
JP2016106092A (ja) 組合せ
CN112237579B (zh) 药物组合及其用途
KR20250002214A (ko) Sos1 억제제 및 mek 억제제를 포함하는 병용 요법
CN112843059A (zh) 一种取代丁烯酰胺的应用
CN117615762A (zh) 组合疗法
HK1091745A (en) Dosing schedule for erbb2 anticancer agents
CN115721649A (zh) 抑制突变型egfr的化合物及其应用
EA048458B1 (ru) Способы комбинированной терапии
HK40035225A (en) Pharmaceutical combination and use thereof
HK40055040A (en) Combination therapies

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued